No abstract available.
Lipoprotein(a)*

No abstract available.
Hypercholesterolemia* ; Lipoprotein-X* ; Lipoproteins*

No abstract available.
Lipoprotein(a)* ; Risk Factors*

Study on 50 patients (male: 12, female: 38), between the ages of 72 and 40, with hypertension (62% of patients), obesity (60%) in which abdominal obesity (78%) was carried out in Bach Mai Hospital during July 2000- March 2001. The results found that the lipemia disorder frequently occurred in patients with reduced glucose toleration according to the classification of Fredrichson (type IV). 69% patients with the reduced glucose toleration had a lipemia disorder accompanying with hypertension. The risk of hypertension among these patients was higher 6.7 times than this among patients without the lipemia disorder. 93% patients with the reduced glucose toleration and obesity had a lipemia disorder. This rate in the patients with abnormal obesity was 97%; 100% of patients with the reduced glucose toleration had signs of coronary insufficiency
Glucose ; Lipoprotein Lipase ; Blood Glucose

A study on the process of treatment of 40 patients with the nephritic syndrome, without the renal failure by prednisolone from 12/1996 to 5/1998 has shown that 100% patients had a high increased concentration of total cholesterol (CT) and low density lipoprotein (LDL); 90% patient had an increased concentration of triglyceride (TG) and 15% patient had an increased concentration of high density lipoprotein (HDL); 100% patients had an increased concentrations of proteinuria over 3.5 g/24 hours. After 2 weeks of treatment, the concentrations of CT, LDL, TG were reduced but were not significant different from these in baseline. The proteinuria was reduced to 40%; concentration of HDL was gradually increased. Their reductions were significant different from these before treatment but risks were high. 75% patients had negative proteinuria.
Nephrotic Syndrome ; Proteinuria ; Lipoprotein Lipase ; therapy ; Lipids

No abstract available.
Cerebral Infarction* ; Korea* ; Lipoprotein(a)* ; Risk Factors*

PURPOSE: We investigated coagulation disorders in Korean patients of idiopathic avascular necrosis of the femoral head. MATERIALS AND METHODS: Ten laboratory parameters related with coagulation pathway were measured and analyzed in fifty-three patients with idiopathic avascular necrosis of the femoral head and compared the results with those of thirty-one healthy persons. RESULTS: Differences in the values of plasminogen activator inhibitor and D-dimer in the two groups were statistically significant (p<0.05). The number of three or four abnormal parameters in the patient group was nearly twice that of the control. Hypofibrinolytic activity, determined by increased plasminogen activator inhibitor and lipoprotein(a), were observed in eleven cases (20.8%) of the patient group. CONCLUSION: The abnormal results that were observed in the patient group may contribute to the predisposition of thrombotic venous occlusion in the head of the femur, leading to avascular necrosis of the femoral head.
Femur ; Head* ; Humans ; Lipoprotein(a) ; Necrosis* ; Plasminogen Activators

Objective: The aim of the study was to assess the effect of rosuvastatin 2.5 mg, an inhibitor of HMG-CoA reductase, on achieving lipid goals defined by the 2007 Japan Atherosclerosis Society guidelines. Subjects and Methods: Thirty-seven patients with moderate to high risk hypercholesterolemia (Mean age: 64.8 ± 8.4) were treated with 2.5 mg/day of rosuvastatin and their lipid and hepatic function parameters were measured at the baseline and at Weeks 4 and 8. Results: At 4 and 8 weeks after start of treatment, 74.1% and 92.6% of moderate risk patients, as well as 70% and 80% of high risk patients, achieved their LDL-C goals, respectively. In both moderate and high risk patients, the mean LDL-C/HDL-C ratio, which is considered as a prospective index for plaque regression, was significantly reduced (p<0.001 for both the moderate and high risk groups), and the mean LDL-C/HDL-C ratio decreased to less than 2 in moderate risk patients. No abnormal changes were observed in hepatic function tests during the study. Conclusion: More than 80% of moderate to high risk patients with hypercholesterolemia achieved their lipid goals and the mean LDL-C/HDL-C ratio was significantly reduced after the 8-week short treatment of rosuvastatin 2.5 mg, suggesting the clinical possibility of continuous use of rosuvastatin for plaque regression.
Carbon ion ; Risk ; Lipids ; Low density lipoprotein cholesterol measurement ; High density lipoprotein measurement

No abstract available.
Female* ; Humans ; Hyperlipoproteinemia Type I* ; Lipoprotein Lipase* ; Lipoproteins*

No abstract available.
Female* ; Humans ; Hyperlipoproteinemia Type I* ; Lipoprotein Lipase* ; Lipoproteins*